TORONTO, Nov. 2 /CNW/ - Bradmer Pharmaceuticals Inc., a biopharmaceutical company dedicated to the development and commercialization of cancer therapies, announced today that its lead product candidate, Neuradiab, has been granted orphan drug status for the treatment of glioblastoma multiforme (GBM) by the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMEA). Bradmer has previously obtained orphan drug status for Neuradiab from the U.S. Food and Drug Administration.
